This research identifies two distinct clones in chronic lymphocytic leukemia (CLL) through single-cell RNA and BCR sequencing, revealing differences in immunoglobulin heavy-chain V region genes and light chains. The study highlights the unique gene expression patterns of these clones, one being unmutated and the other mutated, and tracks their presence over three years without clinical progression, providing insights into the biology of multi-clonal CLL.

The study evaluates the diagnostic and prognostic significance of CD200 and CD43 in distinguishing chronic lymphocytic leukemia (CLL) from the leukemic phase of non-Hodgkin lymphoma (NHL). Findings indicate that CD200 and CD43 expression patterns significantly correlate with CLL and NHL, suggesting their combined use could enhance diagnostic accuracy in these hematological disorders.

This study analyzes the DNA methylome of B-cell prolymphocytic leukemia (B-PLL) cases, revealing that B-PLL is epigenetically distinct from other leukemias and can be divided into two clinicobiological subtypes with differing characteristics. The findings suggest that these subtypes have significant implications for diagnosis and patient prognosis, particularly highlighting that one subtype is associated with poorer overall survival.

The study analyzed the behavior of inflammatory markers, specifically procalcitonin and C-reactive protein, in 22 patients with lymphoproliferative diseases treated with obinotuzumab. Significant increases in these markers were observed shortly after drug administration, but these changes were generally not associated with infections and did not adversely affect treatment outcomes.

This study investigates the effects of the BTK inhibitor ibrutinib on B cells in patients with chronic lymphocytic leukemia (CLL), revealing that clonal stability is maintained in ibrutinib-treated patients despite a high clonal burden. Over a follow-up period of up to 3.2 years, minimal genomic progression was observed, with somatic drivers and variant allele frequencies remaining stable, indicating that ibrutinib may stabilize the genomic landscape of CLL cells.

The 2024 Lymphoma Research Foundation Workshop developed consensus recommendations for the selection and sequencing of therapies for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in the US. These recommendations aim to bridge the gap between existing guidelines and real-world practices, addressing the challenges posed by the shift from traditional chemoimmunotherapy to targeted therapies amidst a lack of randomized clinical trial data.